Cencora, Inc. reported robust financial results for its fiscal year 2024 fourth quarter and full year ended September 30, 2024. Fourth-quarter revenue increased 14.7% year-over-year to $79.1 billion, while full-year revenue rose 12.1% to $294.0 billion.
For the fourth quarter, adjusted diluted EPS increased 16.8% to $3.34, and for the full fiscal year, adjusted diluted EPS grew 14.8% to $13.76. The U.S. Healthcare Solutions segment was a primary driver, with its fourth-quarter revenue increasing 15.7% to $71.7 billion and operating income up 10.2% to $697.4 million.
The company's Board of Directors declared an 8% increase in its quarterly dividend, raising it to $0.55 per common share, payable November 29, 2024. Cencora also introduced its fiscal year 2025 adjusted diluted EPS guidance in the range of $14.80 to $15.10, with projected revenue growth of 7% to 9% and adjusted operating income growth of 5% to 6.5%.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.